Literature DB >> 12589888

Nicotinic mechanisms of memory: effects of acute local DHbetaE and MLA infusions in the basolateral amygdala.

Nii A Addy1, Aya Nakijama, Edward D Levin.   

Abstract

Nicotine has been shown to improve working memory. The neural mechanisms underlying this effect are still being determined. The ventral hippocampus is critical for nicotinic effects on memory. Local ventral hippocampal infusions of either the nicotinic alpha7 nicotinic receptor antagonist methyllycaconitine (MLA) or the alpha4beta2 nicotinic receptor antagonist dihydro-beta-erythroidine (DHbetaE) caused working memory impairments, but no additive effects were seen. Other areas, such as the amygdala, also likely play important roles in nicotinic effects on memory. Amygdalar lesions cause memory impairment and there is a dense concentration of nicotinic receptors in the basolateral amygdala. The current study used local basolateral amygdalar infusions of the nicotinic antagonists MLA and DHbetaE to determine the involvement of alpha7 and alpha4beta2 nicotinic receptors in spatial working and reference memory. Rats (n=8) were trained in the 16-arm radial maze and were implanted with bilateral infusion cannulae into the basolateral amygdala. Acute infusions of MLA (6.75 micro g/side, P<0.0005) or DHbetaE (3.38 micro g/side, P<0.025) caused significant working memory impairments. When given together MLA and DHbetaE did not produce an additive effect. In fact, the 6.75 micro g/kg dose of DHbetaE produced a significant (P<0.0005) attenuation of the MLA-induced working memory impairment. Significant effects were not seen with reference memory or response latency. Nicotinic systems in the basolateral amygdala, as in the ventral hippocampus, are important for spatial working memory. In both the basolateral amygdala and the ventral hippocampus, MLA and DHbetaE individually caused working memory impairments. The lowest effective dose of DHbetaE was lower in the basolateral amygdala than in the ventral hippocampus. In both the basolateral amygdala and the ventral hippocampus, combined MLA and DHbetaE treatment did not produce additive working memory deficits. Unlike in the ventral hippocampus, the addition of DHbetaE to MLA in the basolateral amygdala significantly reduced the MLA-induced working memory deficit.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12589888     DOI: 10.1016/s0926-6410(02)00209-4

Source DB:  PubMed          Journal:  Brain Res Cogn Brain Res        ISSN: 0926-6410


  19 in total

1.  α7-Containing nicotinic acetylcholine receptors on interneurons of the basolateral amygdala and their role in the regulation of the network excitability.

Authors:  Volodymyr I Pidoplichko; Eric M Prager; Vassiliki Aroniadou-Anderjaska; Maria F M Braga
Journal:  J Neurophysiol       Date:  2013-09-04       Impact factor: 2.714

2.  Decreasing nicotinic receptor activity and the spatial learning impairment caused by the NMDA glutamate antagonist dizocilpine in rats.

Authors:  Dennis A Burke; Pooneh Heshmati; Ehsan Kholdebarin; Edward D Levin
Journal:  Eur J Pharmacol       Date:  2014-07-24       Impact factor: 4.432

Review 3.  Forgetfulness during aging: an integrated biology.

Authors:  Paul E Gold; Donna L Korol
Journal:  Neurobiol Learn Mem       Date:  2014-03-24       Impact factor: 2.877

4.  Functional somato-dendritic alpha7-containing nicotinic acetylcholine receptors in the rat basolateral amygdala complex.

Authors:  Rebecca C Klein; Jerrel L Yakel
Journal:  J Physiol       Date:  2006-08-24       Impact factor: 5.182

5.  α7 nicotinic ACh receptors are necessary for memory recovery and neuroprotection promoted by attention training in amyloid-β-infused mice.

Authors:  Milena Telles-Longui; Danilo Mourelle; Natalia Mendes Schöwe; Gabriela Cabett Cipolli; Helena Nascimento Malerba; Hudson Sousa Buck; Tania Araujo Viel
Journal:  Br J Pharmacol       Date:  2019-07-14       Impact factor: 8.739

6.  Glucose attenuates impairments in memory and CREB activation produced by an α4β2 but not an α7 nicotinic receptor antagonist.

Authors:  Ken A Morris; Sisi Li; Duat D Bui; Paul E Gold
Journal:  Neuropharmacology       Date:  2012-11-16       Impact factor: 5.250

7.  Pharmacological and behavioral profile of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141), a novel α7 nicotinic acetylcholine receptor agonist/serotonin 5-HT3 receptor antagonist.

Authors:  Frank G Boess; Jean de Vry; Christina Erb; Timo Flessner; Martin Hendrix; Joachim Luithle; Christoph Methfessel; Katrin Schnizler; F Josef van der Staay; Marja van Kampen; Welf-Burkhard Wiese; Gerhard König
Journal:  Psychopharmacology (Berl)       Date:  2012-12-16       Impact factor: 4.530

8.  Facilitation of cortico-amygdala synapses by nicotine: activity-dependent modulation of glutamatergic transmission.

Authors:  Li Jiang; Lorna W Role
Journal:  J Neurophysiol       Date:  2008-02-13       Impact factor: 2.714

Review 9.  Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

Authors:  Jared W Young; Susan B Powell; Victoria Risbrough; Hugh M Marston; Mark A Geyer
Journal:  Pharmacol Ther       Date:  2009-03-06       Impact factor: 12.310

10.  Varenicline ameliorates ethanol-induced deficits in learning in C57BL/6 mice.

Authors:  Danielle Gulick; Thomas J Gould
Journal:  Neurobiol Learn Mem       Date:  2008-04-14       Impact factor: 2.877

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.